1. In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia.
- Author
-
Gézsi, A, Lautner-Csorba, O, Erdélyi, D J, Hullám, G, Antal, P, Semsei, Á F, Kutszegi, N, Hegyi, M, Csordás, K, Kovács, G, and Szalai, C
- Subjects
- *
LYMPHOBLASTIC leukemia in children , *CANCER chemotherapy , *DRUG metabolism , *SINGLE nucleotide polymorphisms , *GENOTYPES , *PHARMACOGENOMICS , *LEUKEMIA treatment - Abstract
CYP3A4 has an important role in the metabolisms of many drugs used in acute lymphoblastic leukemia (ALL) therapy; still, there are practically no publications about the role of CYP3A4 polymorphisms in ALL pharmacogenomics. We genotyped eight common single-nucleotide polymorphisms (SNPs) in the CYP3A4 and CYP3A5 genes in 511 children with ALL and investigated whether they influenced the survival of the patients. We involved additional 127 SNPs in 34 candidate genes and searched for interactions with respect to the survival rates. Significant association between the survival rates and the common rs2246709 SNP in the CYP3A4 gene was observed. The gender of the patients and the rs1076991 in the MTHFD1 gene strongly influenced this effect. We calculated new risk assessments involving the gender-rs2246709 interaction and showed that they significantly outperformed the earlier risk-group assessments at every time point. If this finding is confirmed in other populations, it can have a considerable prognostic significance. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF